Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers
UroPanc
1 other identifier
observational
3,500
1 country
4
Brief Summary
Urine and blood samples are being collected from patients with and without diseases of the pancreas. These samples will be tested with the aim of developing an accurate way of diagnosing diseases of the pancreas using the results.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2020
Longer than P75 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2020
CompletedFirst Submitted
Initial submission to the registry
May 5, 2020
CompletedFirst Posted
Study publicly available on registry
June 26, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2026
January 7, 2026
January 1, 2026
6.7 years
May 5, 2020
January 5, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Accuracy of biomarker panel and affiliated risk score
Test accuracy, as measured by sensitivity/specificity (SN/SP) and positive predictive value/negative predictive value (PPV/NPV).
Baseline until completion of standard-of-care diagnostic testing (up to 12 months after enrolment)
Secondary Outcomes (2)
Accuracy of biomarker panel and affiliated risk score when combined with CA19-9 result
Baseline until completion of standard-of-care diagnostic testing (up to 12 months after enrolment)
Economic and social impact of using biomarker panel for PDAC testing
Baseline until completion of standard-of-care diagnostic testing (up to 12 months after enrolment)
Study Arms (1)
Individuals at risk of developing PDAC
* Symptomatic participants (via direct recruitment to UroPanc and via study/tissue bank(s) i.e. UCL ADEPTs study) * Asymptomatic participants (via study/tissue bank(s) i.e. University of Liverpool EUROPAC registry) Medical history, demographic information and concomitant medications information will be collected at baseline, together with blood and urine samples. Urinary biomarkers and plasma CA19-9 will be measured and the results compared with imaging data (and pathology, if it becomes available).
Eligibility Criteria
Samples from symptomatic and asymptomatic individuals at risk of PDAC will be provided to the UroPanc team by collaborating centres via dedicated tissue banks/registries already in place at UCL (ADEPTS) and the University of Liverpool (EUROPAC). Symptomatic individuals at risk which are being referred to specialist care by their general practitioners (GPs) will be recruited to participate in UroPanc when attending clinics (gastroenterology clinics, endoscopy units and Multidisciplinary Diagnostic Centres (MDCs)) at a participating study site.
You may qualify if:
- Able and willing to give informed consent
- ≥18 years old
- Suspected pancreatic diseases with symptoms including, but not limited to, diarrhoea, back pain, abdominal pain, nausea, vomiting, constipation or new onset diabetes
You may not qualify if:
- Current or prior treatment (chemotherapy, radiotherapy, surgical resection, biological therapy, and immunotherapy) for any malignancy other than basal cell carcinoma within 5 years of enrolment.
- Asymptomatic participants will be identified through the EUROPAC registry and will fulfil EUROPAC's eligibility criteria.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Queen Mary University of Londonlead
- University of Liverpoolcollaborator
- University College, Londoncollaborator
- Imperial College Londoncollaborator
- Pancreatic Cancer Research Fundcollaborator
- Ospedale San Raffaelecollaborator
Study Sites (4)
EUROPAC study, University of Liverpool
Liverpool, United Kingdom
ADEPTS study, University College London
London, United Kingdom
Imperial College London
London, United Kingdom
Royal London Hospital
London, United Kingdom
Related Publications (2)
Radon TP, Massat NJ, Jones R, Alrawashdeh W, Dumartin L, Ennis D, Duffy SW, Kocher HM, Pereira SP, Guarner posthumous L, Murta-Nascimento C, Real FX, Malats N, Neoptolemos J, Costello E, Greenhalf W, Lemoine NR, Crnogorac-Jurcevic T. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. Clin Cancer Res. 2015 Aug 1;21(15):3512-21. doi: 10.1158/1078-0432.CCR-14-2467.
PMID: 26240291BACKGROUNDBlyuss O, Zaikin A, Cherepanova V, Munblit D, Kiseleva EM, Prytomanova OM, Duffy SW, Crnogorac-Jurcevic T. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients. Br J Cancer. 2020 Mar;122(5):692-696. doi: 10.1038/s41416-019-0694-0. Epub 2019 Dec 20.
PMID: 31857725BACKGROUND
Biospecimen
Urine and blood samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Tatjana Crnogorac-Jurcevic, MD, PhD
Queen Mary University of London
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 5, 2020
First Posted
June 26, 2020
Study Start
January 1, 2020
Primary Completion (Estimated)
August 31, 2026
Study Completion (Estimated)
August 31, 2026
Last Updated
January 7, 2026
Record last verified: 2026-01